2018
A pilot study of omalizumab to reduce the incidence of oxaliplatin-induced hypersensitivity reaction (HSR): An interim analysis.
Stein S, Uboha N, Dooley K, Hochster H. A pilot study of omalizumab to reduce the incidence of oxaliplatin-induced hypersensitivity reaction (HSR): An interim analysis. Journal Of Clinical Oncology 2018, 36: e15555-e15555. DOI: 10.1200/jco.2018.36.15_suppl.e15555.Peer-Reviewed Original Research
2014
Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors.
Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.Peer-Reviewed Original Research